Stimcell Energetics (STME) Cash from Operations Growth (3y) (2016 - 2026)
Stimcell Energetics (STME) Cash from Operations Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.73 Bn | 176.43 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.82 Bn | 125.94 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 108.74 Bn | 99.52 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.40 Bn | 66.95 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 47.42 Bn | 43.74 Bn | 1.29 Bn | -48.14% |
| 6 | GE HealthCare Technologies | 28.47 Bn | 26.18 Bn | 1.98 Bn | -14.75% |
| 7 | Dexcom | 28.42 Bn | 27.30 Bn | 750.30 Mn | 50.11% |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.52 Bn | 22.39 Bn | 2.07 Bn | 0.50% |
| 10 | Stimcell Energetics | 5.85 Mn | 5.84 Mn | - | 5.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 5.84% |
| Nov 30, 2025 | -3.14% |
| Aug 31, 2025 | -12.65% |
| May 31, 2025 | 14.82% |
| Feb 28, 2025 | 20.73% |
| Nov 30, 2024 | 47.92% |
| Aug 31, 2024 | 46.70% |
| May 31, 2024 | 39.80% |
| Feb 29, 2024 | 27.30% |
| Nov 30, 2023 | 37.42% |
| Aug 31, 2023 | 38.04% |
| May 31, 2023 | 51.91% |
| Feb 28, 2023 | 21.79% |
| Nov 30, 2022 | 37.42% |
| Aug 31, 2022 | 28.12% |
| May 31, 2022 | 2.50% |
| Feb 28, 2022 | 14.83% |
| Nov 30, 2021 | -90.74% |
| Aug 31, 2021 | -48.10% |
| May 31, 2021 | -68.78% |